Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

BACKGROUND: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma. METHODS: Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and da...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2012
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251861/
https://ncbi.nlm.nih.gov/pubmed/22127285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.514
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы